A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans

Trial Profile

A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Intestinal infections
  • Focus Diagnostic use
  • Most Recent Events

    • 13 Apr 2015 New trial record
    • 01 Oct 2014 Endpoint has been met (SUVmax of FDG in each colonic segment), according to results published in the Nuclear Medicine Communications.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top